Kidney and Bladder Cancer: Biology and Patient Management

This interdisciplinary, one-day conference will provide a clinical update on the biology, therapeutic modalities and management decision making in patients with kidney and bladder (urothelial) cancers. Engaging didactic lectures will present current science, ongoing clinical trials and future research directions including many revolutionary advances in multi-disciplinary management approaches to patients with early stage, high risk, and metastatic disease. Interactive discussions with experts in the field will enhance the learning experience.

Learning Objectives

• Analyze and apply new insights into kidney cancer biology for treatment of patients with advanced disease

• Apply emerging results from adjuvant therapy trials to postoperative management with systemic therapy

• Review and apply NCCN and AUA guidelines and consider resection by TURBT to obtain an adequate pathologic specimen whenever feasible

• Effectively use published criteria for cisplatin use regardless of age to optimize survival

• Consider the role of promising new investigational therapies (immune checkpoint inhibitors) available through clinical trials and refer patients accordingly